Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2023-11-28 Legal Proceedings Report
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Legal Proceedings Report 2023
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement dated November 28, 2023, titled "Meddelelse nr. 46" (Announcement no. 46) from Pharma Equity Group A/S. It discusses the status of a receivable from Portinho S.A., delays in expected repayment, ongoing legal/financial investigations, and capital maintenance activities (taking out loans due to delayed payment). Crucially, the document ends with contact information and a link to an attached file: "- [2023 11 28 - Announcement no. 46 - DK]". This structure—a brief update announcing the publication of information and providing a link to the full details—fits the definition of a Report Publication Announcement (RPA). It is not the full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT). Given its nature as a formal, time-sensitive regulatory update that announces the availability of further details, RPA is the most appropriate classification, although RNS is a close secondary option if RPA were unavailable. Since RPA specifically covers announcements about the publication of reports/information, it is preferred here.
2023-11-28 Danish
Status of the Company's receivable from Portinho S.A.
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Meddelelse nr. 46) from Pharma Equity Group regarding the status of a specific receivable (Portinho S.A.) and capital/financing updates. It is not a full report, but rather a regulatory update on company operations and financial status. Since it does not fit into specific categories like earnings releases or dividend notices, and serves as a general regulatory update for shareholders, it is best classified as a Regulatory Filing (RNS).
2023-11-28 Danish
Status of the Company's receivable from Portinho S.A.
Regulatory Filings Classification · 95% confidence The document is a short company announcement (under 5,000 characters) regarding the status of a specific receivable from Portinho S.A. It discusses legal investigations, capital implications, and ongoing dialogues. It does not fit into specific categories like 10-K, ER, or M&A. While it mentions an attachment, the content itself provides substantive updates on a specific corporate issue rather than just announcing the publication of a separate report. Therefore, it is best classified as a general regulatory announcement (RNS).
2023-11-28 Danish
Regulatory Filings 2023
Regulatory Filings Classification · 96% confidence The document is a 'Company Announcement no. 45' dated November 16, 2023, reporting positive preliminary results from a Phase-2 clinical trial for a drug candidate (RNX-051). It details the meeting of primary endpoints related to cancer treatment and mentions that a complete analysis is expected in early 2024. This is a specific, material update regarding clinical development and scientific findings, not a full financial report (10-K, IR), a general earnings release (ER), or a management discussion (MDA). It is a specific announcement of scientific/clinical progress. Since there is no specific category for 'Clinical Trial Results Announcement', and it is a material, non-financial regulatory update, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard announcements, or potentially 'LTR' if interpreted as a report on regulatory/scientific progress, but RNS is the most appropriate fallback for a general company announcement of this nature that isn't covered by the other specific codes. Given the context of reporting scientific milestones, RNS is the most suitable general regulatory announcement code.
2023-11-16 English
Legal Proceedings Report 2023
Legal Proceedings Report Classification · 99% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) dated November 16, 2023, detailing positive preliminary results from a Phase 2 clinical study for a drug candidate (RNX-051). It announces key scientific findings ('primary endpoints achieved', 'Topline results') related to cancer treatment and mentions that full results are expected in early 2024. This type of announcement, which releases preliminary or key financial/operational results for a period or event (like clinical trial success) without being the full quarterly/annual report or a transcript, aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of operational/scientific progress rather than strictly financial earnings, and it is a formal company communication, it fits the pattern of an initial results announcement. Given the options, 'ER' (Earnings Release) is often used broadly for initial results announcements, but 'RNS' (Regulatory Filings) is a strong fallback for specific operational updates that aren't standard financial reports. However, clinical trial updates are often treated similarly to earnings releases in terms of market impact. Since this is a specific, non-financial operational update (clinical trial success), and it is not a full report, 'RNS' is the most appropriate general regulatory category if 'ER' is reserved strictly for financial performance summaries. Given the context of announcing key operational milestones that impact valuation, it functions like an ER. I will classify it as RNS as it is a general regulatory announcement about a significant operational event, which is the fallback for specific announcements not covered elsewhere.
2023-11-16 Danish
Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.
Regulatory Filings Classification · 98% confidence The document is a corporate announcement regarding clinical trial results (Phase 2 study for RNX-051). It is titled 'Selskabsmeddelelse' (Company Announcement) and provides a summary of the trial outcomes. Since it is a general regulatory announcement regarding company operations and clinical progress that does not fit into specific categories like financial reports or M&A, it is classified as a Regulatory Filing (RNS).
2023-11-16 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.